WEKO3
アイテム
Precision measurement of fluid biomarkers for the multicenter imaging cohort study (MABB).
https://repo.qst.go.jp/records/84380
https://repo.qst.go.jp/records/84380ab230078-d03f-4d98-ab85-120bee63b93c
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2021-12-24 | |||||
| タイトル | ||||||
| タイトル | Precision measurement of fluid biomarkers for the multicenter imaging cohort study (MABB). | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Takahiko, Tokuda
× Takahiko, Tokuda× Takahiko, Tokuda |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Title: Precision measurement of fluid biomarkers for the multicenter imaging cohort study (MABB) 多施設共同イメージングコホート研究(MABB)における体液バイオマーカーの精密定量 There is still a substantial unmet need for less invasive and lower-cost molecular biomarkers, namely blood-based biomarkers, for the diagnosis and stratification of patients with dementia including Alzheimer's disease (AD). We developed the world's first immunoassay to quantify plasma tau phosphorylated at threonine 181 (p-tau181) in 2017 by using an ultrasensitive digital array technology (Simoa system, Quanterix, USA). With this original assay, we reported that the plasma levels of p-tau181 were significantly higher in AD patients than those in the controls. Our study suggested that plasma p-tau181 is a promising blood biomarker for brain AD pathology. After our study, substantial evidence of the usefulness of plasma p-tau assays in the diagnosis of AD has been accumulating internationally. Now, we are developing other blood biomarkers for AD, such as Aβ42/40 and neurofilament light (NfL) as well as those for other dementing diseases, such as TDP-43 and α-synuclein. Furthermore, in order to validate the usefulness of those blood-based biomarkers, it is essential that we should collect large-scale blood samples obtained from patients with a highly reliable diagnosis of underlying diseases. Such a "reliable diagnosis" used to mean the pathological diagnosis of the patients, but now neuroimaging techniques, such as PET imaging, of pathognomonic accumulation of abnormal protein aggregates can be a substitute for the pathological diagnosis. From this recognition, we have just launched the Multicenter Alliance for Brain Biomarkers (MABB) in August 2020. Now 13 institutes including QST have joined the MABB and started to enroll patients with cognitive impairment and controls to collect both PET imaging data and blood samples. In this talk, I will present our results regarding blood-based biomarkers for AD and neurodegenerative diseases, and introduce the MABB cohort. |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 日本神経学会学術大会 | |||||
| 発表年月日 | ||||||
| 日付 | 2021-05-19 | |||||
| 日付タイプ | Issued | |||||
